Abbott Laboratories

Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and healthcare company headquartered in Abbott Park, Illinois. Founded in Chicago in 1888 by Dr. Wallace C. Abbott, it was initially known as the Abbott Alkaloidal Company. Abbott is a publicly traded company on the New York Stock Exchange under the ticker symbol ABT. As of June 2026, the company has a market capitalization of approximately $153.59 billion USD to $174.69 billion USD. It employs around 114,000 to 122,000 people globally and reported annual revenue of $44.3 billion in 2025, with a trailing twelve months revenue of $45.134 billion as of March 31, 2026.

Abbott's operations span four key segments: Medical Devices, Diagnostics, Nutritional Products, and Established Pharmaceutical Products. Its medical device portfolio includes cardiovascular devices like MitraClip and FreeStyle Libre continuous glucose monitoring systems for diabetes care, as well as neuromodulation devices for pain and movement disorders. The diagnostics division offers a range of systems and tests for blood banks, hospitals, and at-home use. Notable nutritional products include Similac for pediatric nutrition and Ensure and Glucerna for adult nutrition. Its established pharmaceutical segment focuses on branded generic medicines primarily marketed outside the United States.

In terms of patent litigation, Abbott Laboratories demonstrates an active, two-way posture, engaging as both a plaintiff and a defendant. The company has been involved in 7 tracked cases, appearing as a plaintiff in 4 cases and as a defendant in 3 cases. All current tracked cases since late 2023 involve Miracor Medical SA, primarily within the Patent Trial and Appeal Board (PTAB) and the U.S. District Court for the Northern District of Illinois. The cases indicate that Abbott is an operating company actively protecting its intellectual property and defending against infringement allegations.